140 related articles for article (PubMed ID: 8820920)
1. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin.
Nagasawa K; Natazuka T; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Jan; 19(1):100-5. PubMed ID: 8820920
[TBL] [Abstract][Full Text] [Related]
2. Transport mechanism of pirarubicin in human mononuclear cells.
Nagasawa K; Tsumura A; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Sep; 19(9):1203-9. PubMed ID: 8889041
[TBL] [Abstract][Full Text] [Related]
3. Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells.
Nagasawa K; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Jul; 19(7):971-6. PubMed ID: 8839972
[TBL] [Abstract][Full Text] [Related]
4. Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs.
Nagasawa K; Ohnishi N; Yokoyama T
Jpn J Cancer Res; 1997 Aug; 88(8):750-9. PubMed ID: 9330607
[TBL] [Abstract][Full Text] [Related]
5. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells.
Nagasawa K; Natazuka T; Chihara K; Kitazawa F; Tsumura A; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Cancer Chemother Pharmacol; 1996; 37(4):297-304. PubMed ID: 8548874
[TBL] [Abstract][Full Text] [Related]
6. Contribution of the nucleoside transport system to doxorubicin transport in HL60 cells but not in mononuclear cells.
Nagasawa K; Fumihara T; Ohnishi N; Yokoyama T
Jpn J Cancer Res; 1999 Jul; 90(7):781-7. PubMed ID: 10470292
[TBL] [Abstract][Full Text] [Related]
7. Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein.
Gupta S; Patel K; Singh H; Gollapudi S
Cancer Lett; 1994 Jan; 76(2-3):139-45. PubMed ID: 7511983
[TBL] [Abstract][Full Text] [Related]
8. Possibility of contribution of nucleoside transport systems to pirarubicin uptake by HL60 cells but not mononuclear cells.
Nagasawa K; Ohnishi N; Yokoyama T
Jpn J Cancer Res; 1998 Jun; 89(6):673-80. PubMed ID: 9703366
[TBL] [Abstract][Full Text] [Related]
9. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells.
Versantvoort CH; Broxterman HJ; Lankelma J; Feller N; Pinedo HM
Biochem Pharmacol; 1994 Sep; 48(6):1129-36. PubMed ID: 7945406
[TBL] [Abstract][Full Text] [Related]
10. ATP-dependent transport of lipophilic cytotoxic drugs by membrane vesicles prepared from MRP-overexpressing HL60/ADR cells.
Paul S; Breuninger LM; Kruh GD
Biochemistry; 1996 Nov; 35(44):14003-11. PubMed ID: 8909298
[TBL] [Abstract][Full Text] [Related]
11. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells.
Gollapudi S; Kim CH; Tran BN; Sangha S; Gupta S
Cancer Chemother Pharmacol; 1997; 40(2):150-8. PubMed ID: 9182837
[TBL] [Abstract][Full Text] [Related]
12. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy.
Gervasoni JE; Fields SZ; Krishna S; Baker MA; Rosado M; Thuraisamy K; Hindenburg AA; Taub RN
Cancer Res; 1991 Sep; 51(18):4955-63. PubMed ID: 1680024
[TBL] [Abstract][Full Text] [Related]
13. Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
Friche E; Demant EJ; Sehested M; Nissen NI
Br J Cancer; 1993 Feb; 67(2):226-31. PubMed ID: 8094288
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the binding of anthracycline derivatives to purified DNA and to cell nuclei.
Frezard F; Garnier-Suillerot A
Biochim Biophys Acta; 1990 Nov; 1036(2):121-7. PubMed ID: 2223830
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
[TBL] [Abstract][Full Text] [Related]
16. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
[TBL] [Abstract][Full Text] [Related]
17. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein.
Benderra Z; Trussardi A; Morjani H; Villa AM; Doglia SM; Manfait M
Eur J Cancer; 2000 Feb; 36(3):428-34. PubMed ID: 10708946
[TBL] [Abstract][Full Text] [Related]
18. A model for computer simulation of P-glycoprotein and transmembrane delta pH-mediated anthracycline transport in multidrug-resistant tumor cells.
Demant EJ; Sehested M; Jensen PB
Biochim Biophys Acta; 1990 Nov; 1055(2):117-25. PubMed ID: 2242381
[TBL] [Abstract][Full Text] [Related]
19. Transport mechanism of anthracycline derivatives in rat polymorphonuclear leukocytes: uptake of pirarubicin, daunorubicin and doxorubicin.
Nagasawa K; Nomiyama M; Ohnishi N; Yokoyama T; Iwakawa S; Okumura K
Biol Pharm Bull; 1994 Sep; 17(9):1305-8. PubMed ID: 7841960
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric monitoring of cellular anthracycline accumulation in murine leukemic cells.
Krishan A; Sauerteig A; Gordon K; Swinkin C
Cancer Res; 1986 Apr; 46(4 Pt 1):1768-73. PubMed ID: 3948163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
